You are here:

Forthcoming Submission: trastuzumab emtansine (Kadcyla)

Indication: As a single agent for the treatment of adult patients with HER2-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: • received prior therapy for locally advanced or metastatic disease, or • developed disease recurrence during or within six months of completing adjuvant therapy.

Drug Details

Drug Name: trastuzumab emtansine (Kadcyla)
Drug Manufacturer: Roche
BNF Category:
Submission type: Full submission
Patient Interest Group
Submission Deadline:
SMC Meeting Date: 2/09/2014
Advice Due: 13/10/2014